MRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
MARAVAI LIFESCIENCES HOLDINGS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$6.99+0.20 (+2.95%)
Close on Oct 19, 2026
- Market cap
- $1.03B
- P/E (TTM)
- –
- Dividend yield
- –
MARAVAI LIFESCIENCES HOLDINGS, INC. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TriLink | $34.67M | $47.48M | – | – | $31.09M | $28.75M | – | – | – | – | – | – | 67.4% | +11.5% |
| Cygnus | $16.77M | $18.36M | – | – | $16.31M | $18.10M | – | – | – | – | – | – | 32.6% | +2.8% |
| Cygnus | – | $18.36M | – | $16.28M | $16.31M | $18.10M | $14.66M | $15.18M | $14.84M | $18.16M | $15.32M | $15.64M | – | – |
| TriLink | – | $47.48M | – | $25.35M | $31.09M | $28.75M | $41.90M | $53.84M | $54.59M | $46.02M | $58.83M | $51.23M | – | – |
By product or service
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | $31.28M | $35.69M | $27.44M | $25.03M | $30.64M | $29.27M | $26.86M | $34.62M | $32.24M | $33.37M | $31.70M | $34.52M | 60.8% | +2.1% |
| United States | $30.90M | $35.20M | – | – | $30.30M | $28.80M | – | – | – | – | – | – | 60.1% | +2.0% |
| Europe, the Middle East and Africa | $10.45M | $21.95M | $7.68M | $7.97M | $8.40M | $6.88M | $7.68M | $11.36M | $13.65M | $9.37M | $16.16M | $7.62M | 20.3% | +24.5% |
| Asia Pacific | $9.32M | $7.87M | $14.42M | $8.34M | $8.16M | $10.56M | $21.91M | $22.92M | $23.42M | $21.14M | $26.13M | $24.62M | 18.1% | +14.2% |
| Latin and Central America | $386.00K | $329.00K | $324.00K | $296.00K | $205.00K | $146.00K | $109.00K | $125.00K | $121.00K | $307.00K | $154.00K | $105.00K | 0.8% | +88.3% |
From the segment and revenue-disaggregation notes of Maravai Lifesciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.